通过新型小分子MRGPRX2抗剂抑制瘤细胞脱粒化
Joshua Wollam1, Michelle Solomon1, Christiane Villescaz1
1Escient Pharmaceuticals, San Diego, Calif.
The Journal of allergy and clinical immunology
|July 6, 2024
概括
新型小分子对Mas相关G蛋白结合受体X2 (MRGPRX2) 的抗体有效抑制了巨细胞脱粒化. 这些MRGPRX2抗剂在治疗各种巨细胞介导疾病方面表现有前途.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 与Mas相关的G蛋白结合受体X2 (MRGPRX2) 是IgE独立质细胞脱粒化的关键调解者.
- MRGPRX2与慢性疹,亚托皮炎和疼痛等疾病有关,但缺乏强效的选择性对抗剂.
- 人体MRGPRX2抑制的功能性作用在体内仍然未被评估.
研究的目的:
- 识别和描述新型,强效和选择性口服活性小分子MRGPRX2抗剂.
- 为了评估巨细胞介导疾病的治疗潜力.
主要方法:
- 在过度表达人类MRGPRX2的细胞系和各种原发性巨细胞类型中利用了多重功能测定.
- 在MRGPRX2试验小鼠中评估了皮肤杆细胞脱粒和血管透性.
- 通过微透析评估了 ex vivo 人体皮肤巨细胞脱粒和组胺释放.
主要成果:
- MRGPRX2对抗剂显示出对激素诱导的MRGPRX2激活和巨细胞降粒的强有力的抑制.
- 口服的抗体降低了MRGPRX2敲进小鼠的脱粒和血管透性.
- 对抗剂治疗剂量依赖地抑制了 ex vivo 人体皮肤样本中的脱粒化.
结论:
- 小分子MRGPRX2抗剂在人体皮肤中的体外,体内和体外都能有效抑制杆细胞脱粒化.
- 这些发现支持MRGPRX2抗剂对涉及质细胞激活的疾病的治疗效用.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
267
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
267
GPCR Desensitization
5.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
158
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
158
Antiasthma Drugs: Muscarinic Receptor Antagonists
280
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
280
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Drugs Acting on Autonomic Ganglia: Blockers
991
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
991


